Atara Biotherapeutics’ EMBOLD Study Fails to Meet Primary Endpoint in Multiple Sclerosis Trial, Stock Falls
Atara Biotherapeutics, a leading biotechnology company, witnessed a sharp decline in its stock value today following the release of disappointing results from its Phase 2
